Myasthenia Gravis Treatment Market Report 2026

The myasthenia gravis treatment market size has grown strongly in recent years. It will grow from $1.66 billion in 2025 to $1.79 billion in 2026 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to increasing prevalence of autoimmune disorders, early adoption of corticosteroids, widespread clinical use of cholinesterase inhibitors, expansion of hospital-based mg treatment programs, rising awareness of neuromuscular diseases.

The myasthenia gravis treatment market size is expected to see strong growth in the next few years. It will grow to $2.43 billion in 2030 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to growth in monoclonal antibody development, increasing demand for minimally invasive surgery, expansion of specialty clinics, rising use of ivig and advanced immunotherapies, enhanced diagnostic capabilities through ai-based tools. Major trends in the forecast period include rising adoption of immunosuppressive therapies, growing use of monoclonal antibodies for mg treatment, increasing preference for minimally invasive thymectomy, higher demand for ivig and plasmapheresis in severe cases, expansion of supportive and combination therapy approaches.

The increasing prevalence of myasthenia gravis is expected to drive the growth of the myasthenia gravis treatment market going forward. Myasthenia gravis is an autoimmune neuromuscular disorder characterized by fatigue and weakness of the skeletal muscles. Treatment for myasthenia gravis involves the delivery of healthcare services and therapeutic interventions aimed at managing symptoms and improving muscle function. As a result, the rising prevalence of the disease is contributing to increased demand for treatment options and boosting market growth. For instance, in January 2024, according to Myaware, a UK-based charity, based on a United Kingdom population of approximately 67,817,100, an estimated 22,855 individuals were living with myasthenia gravis, 204 with Lambert-Eaton myasthenic syndrome, and 2,103 with congenital myopathies. Therefore, the growing prevalence of myasthenia gravis is driving the expansion of the myasthenia gravis treatment market.

Major companies operating in the myasthenia gravis treatment market are focusing on developing innovative products, such as self-administered complement C5 inhibitors, to improve treatment convenience, enhance patient independence, and reduce dependence on infusion-based therapies. Self-administered complement C5 inhibitors are targeted autoimmune treatments designed for subcutaneous administration, allowing patients to manage excessive complement activation at home rather than in clinical infusion settings. For instance, in October 2023, UCB Pharma, a Belgium-based pharmaceutical company, announced that the US Food and Drug Administration (FDA) approved Zilucoplan for the treatment of adults with generalized myasthenia gravis (gMG) who are positive for anti-acetylcholine receptor (AChR) antibodies. This approval introduced a new therapeutic option for managing gMG, a condition marked by muscle weakness resulting from an autoimmune response. ZILBRYSQ is distinguished as a once-daily, self-administered subcutaneous complement C5 inhibitor, offering a convenient alternative to traditional intravenous treatments.

In November 2023, Selecta Biosciences Inc., a US-based biotechnology company, merged with Cartesian Therapeutics for an undisclosed amount. This merger reinforces Selecta’s focus on RNA-based cell therapies for autoimmune diseases, particularly myasthenia gravis. The collaboration aims to leverage Cartesian’s advanced RNA-engineering platform and development pipeline, including the rCAR-T therapy Descartes-08, to accelerate development efforts and deliver effective treatment solutions. Cartesian Therapeutics is a US-based biotechnology company engaged in developing potential therapies for generalized myasthenia gravis.

Major companies operating in the myasthenia gravis treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., Biogen Idec, CSL Limited, Chugai Pharmaceutical Co. Ltd., Grifols S.A, UCB Inc., Mitsubishi Tanabe Pharma Corp., Genentech Inc., Horizon Therapeutics plc, Amneal Pharmaceuticals Inc., Argenx SE, Immunovant Inc., Cabaletta Bio Inc., RemeGen Co. Ltd., Kedrion SpA.

North America was the largest region in the myasthenia gravis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the myasthenia gravis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the myasthenia gravis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs on pharmaceutical ingredients, medical devices, and imported immunotherapy products have increased overall treatment costs in the myasthenia gravis treatment market, particularly affecting regions dependent on foreign drug supply such as Asia-Pacific, South America, and Eastern Europe. Segments most affected include monoclonal antibodies, immunosuppressants, and medical equipment used in thymectomy and plasmapheresis procedures. Although tariffs raise manufacturing and procurement expenses, they also stimulate domestic production capacity, encouraging local pharmaceutical manufacturing and reducing long-term dependency on imports.

The myasthenia gravis treatment market research report is one of a series of new reports that provides myasthenia gravis treatment market statistics, including myasthenia gravis treatment industry global market size, regional shares, competitors with a myasthenia gravis treatment market share, detailed myasthenia gravis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the myasthenia gravis treatment industry. This myasthenia gravis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Myasthenia gravis treatment refers to the provision of healthcare services aimed at managing and treating myasthenia gravis, an autoimmune neuromuscular disorder that causes fatigue and weakness in skeletal muscles.

The main treatments for myasthenia gravis include medication, surgery, and other approaches. Medications are drugs used to manage conditions such as myasthenia gravis. Pyridostigmine is a commonly prescribed medication that helps improve the transmission of electrical signals between nerves and muscles. Treatment for myasthenia gravis involves various medication classes, including cholinesterase inhibitors, corticosteroids, immunosuppressants, and others, and is administered by hospitals, clinics, and other healthcare settings.

The myasthenia gravis treatment market consists of sales of pyridostigmine, prednisone, azathioprine, and cyclosporine. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.